Construction of MMSN@Gem and its inhibition of proliferation and promotion of apoptosis in human bladder cancer cell line BIU-87

doi:10.16352/j.issn.1001-6325.2025.06.0777

Abstract

Abstract: Objective To prepare a multifunctional mesoporous silica-based nanocarrier system(MMSN@Gem) with gemcitabine and investigate its effect on bladder cancer cells BIU-87. Methods The multifunctional mesoporous silica-based nano drug-carrying system was prepared by a modified method. Transmission electron microscopy, high-performance liquid chromatography, and thermal imaging were used to characterize the morphology, drug-carrying and photothermal properties of MMSN@Gem. The effect of MMSN@Gem on BIU-87 bladder cancer cells was detected by in vitro experiments. Results MMSN@Gem exhibited a well-defined spherical morphology with an average particle size of(102.48±1.03)nm with a drug loading capacity of 25.04%±0.17%, and an average zeta potential of(-24.84±0.07)mV. The photothermal conversion efficiency was 40.7% which significantly enhanced the release of Gem under near-infrared irradiation. In vitro studies showed that MMSN@Gem significantly inhibited BIU-87 cell activity, induced apoptosis of BIU-87 cells, reduced migration and invasion ability, and enhanced its uptake by BIU-87 cells. Conclusions MMSN@Gem exhibits excellent photothermal properties, enhances cellular uptake efficiency, inhibits the proliferation and migration of BIU-87 cells, and promotes apoptosis, providing a promising drug delivery system for the clinical treatment of bladder cancer.

Key words: gemcitabine, nano co-loading system, bladder tumour, mesoporous silica

CLC Number:

R945

WANG Daya, LI Zhijia, ZHAO Dewei, CHEN Ximeng. Construction of MMSN@Gem and its inhibition of proliferation and promotion of apoptosis in human bladder cancer cell line BIU-87[J]. Basic & Clinical Medicine, 2025, 45(6): 777-785.

References 15

[1]	Martin A, Woolbright BL, Umar S, et al. Bladder cancer, inflammageing and microbiomes[J]. Nat Rev Urol, 2022, 19: 495-509.
[2]	Aly A, Johnson C, Doleh Y, et al. The real-world lifetime economic burden of urothelial carcinoma by stage at diagnosis[J]. J Clinl Pathw, 2020, 6: 51-60.
[3]	Schlack K, Boegemann M, Steinestel J, et al. The safety and efficacy of gemcitabine for the treatment of bladder cancer[J]. Expert Rev Anticancer Ther, 2016, 16: 255-271.
[4]	周昌东, 林洋, 孙凯, 等. 敲降lncRNA UCA1降低人膀胱癌细胞系T24对吉西他滨耐药[J]. 基础医学与临床, 2024, 44: 1113-1119.
[5]	齐玲玲, 高钟镐, 黄伟. 膀胱癌纳米给药系统研究进展[J], 国际药学研究杂志, 2020, 47: 907-913.
[6]	杨惠舒, 李乐, 刘馨谣, 等. 介孔二氧化硅纳米颗粒作为药物载体的研究现状[J]. 材料导报, 2022, 36: 56-61.
[7]	Estelrich J, Busquets MA. Iron oxide nanoparticles in photothermal therapy[J]. Molecules, 2018,23:1567. doi: 10.3390/molecules23071567.
[8]	Wang Y, Gu H. Core-shell-type magnetic mesoporous silica nanocomposites for bioimaging and therapeutic agent delivery[J]. Adv Mater, 2015, 27: 576-585.
[9]	焦越, 褚伟鹏, 丁宪喆, 等. Fe3O4磁流体集热工质光热转换特性研究[J]. 化工新型材料, 2023, 51: 260-266+272.
[10]	全棋, 管时伟, 林泉, 等. 搭载吉西他滨的SiO2@Fe3O4纳米材料抑制裸鼠胰腺癌移植瘤生长的实验研究[J]. 肝胆胰外科杂志, 2023, 35: 747-752+756.
[11]	Wang D, Li X, Li X, et al. Magnetic and pH dual-responsive nanoparticles for synergistic drug-resistant breast cancer chemo/photodynamic therapy[J]. Int J Nanomedicine, 2019, 147665-147679.
[12]	Knežević N, Lin V S. A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug[J]. Nanoscale, 2013, 5: 1544-1551.
[13]	Li W, Li F, Zhang Y, et al. X-linked inhibitor of apoptosis protein(XIAP)-loaded magnetic mesoporous silica nanoparticles incorporated with miR-233 to improve radio sensitization of cervical cancer cells and promote apoptosis[J]. J Biomed Nanotechnol, 2022, 18: 747-753.
[14]	Yin H, Yang X, Gu W, et al. HMGB1-mediated auto-phagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation[J]. Oncotarget, 2017, 8: 71642-71656.
[15]	Ansari L, Jaafari MR, Bastami TR, et al. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies[J]. Artif Cells Nanomed Biotechnol, 2018, 46: 594-606.